CURRICULUM VITAE (January, 2025)

Rudolph Modesto Navari, M.D., Ph.D., F.A.C.P
.

CURRENT POSITION: Hematologist Oncologist
4518 Crown Point Lane
Birmingham, AL 35117
T: 574 261 8385– Fax: (205) 285 5271
E-mail: rmnavari@gmail.com

EDUCATION:

1966	B.S., Chemical Engineering, University of Notre Dame
1968	M.S., Chemical Engineering, University of Virginia
1970	Ph.D., Chemical Engineering, University of Virginia
1977	M.D., Medical College of Virginia

PROFESSIONAL EXPERIENCE:

1968 - 1969	Instructor in Chemical Engineering, University of Virginia
1970 - 1971	Instructor, American Institute of Chemical Engineers Continuing Education Program, "Surface Chemistry"
1970 - 1971	Research Scientist, Research and Development Center, Union Camp Corporation, Princeton, New Jersey
1971 - 1973	Assistant Professor of Chemistry, Hollins College Roanoke, Virginia
1974 - 1977	Research Associate, Department of Medicine, Medical College of Virginia Richmond, Virginia
1977 - 1978	Intern, Department of Internal Medicine, University of Alabama, Birmingham
1978 - 1980	Resident, Department of Internal Medicine, University of Alabama, Birmingham
1980 - 1981	Chief Resident and Instructor in Medicine, University of Alabama, Birmingham

HELSINN EXHIBIT 2044
Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A.
IPR2025-00947

1981 - 1983	Fellow, Division of Medical Oncology, Department of Medicine University of Washington and the Fred Hutchinson Cancer Research Center, Seattle, Washington
1983 – 1998	Staff Physician, Internal Medicine and Medical Oncology, Simon-Williamson Clinic, Birmingham, Alabama Baptist Medical Center - Princeton, Birmingham, Alabama Bessemer Carraway Medical Center, Bessemer, Alabama
1983- 1998	Clinical Instructor, Medical Residency Program Baptist Health Care System, Birmingham, Al
1987 – 1998	Advisory Council, College of Science University of Notre Dame (Chairman, 1991 - 1992)
1989 - 1992	Chairman, Department of Medicine Simon-Williamson Clinic, P.A. Birmingham, Alabama
1989 – 1998	Director, Bone Marrow Transplantation Program Baptist Medical Center Princeton Birmingham, Alabama
1990 – 1998	Chairman, Comprehensive Cancer Committee Gordon L. Ross Cancer Center Baptist Medical Center - Princeton
1992 – 1998	Medical Director, Hospice Program Bessemer Carraway Medical Center
1992 - 1995	President, Simon-Williamson Clinic, P.C. Birmingham, Alabama
1993 – 1998	Chairman, Cancer Committee Bessemer Carraway Medical Center
1993 – 1998	Member, Joint Policy Board PhyCor of Birmingham

PROFESSSIONAL EXPERIENCE (cont.)

1995 - 1996	Instructor, Alabama School of Mathematics and Science Birmingham, Alabama
1997- 1999	Chairman, Oncology Care Management Council, PhyCor, Inc., Nashville, Tennessee
1998 – 1999	Fellow, MacLean Center for Clinical Medical Ethics, University of Chicago School of Medicine
1999 – 2001, 2007 – 2014	Hematologist – Oncologist South Bend Clinic
1999 – 2005	Director, Walther Cancer Research Center Professional Specialist, Department of Pre-Professional Studies College of Science University of Notre Dame
2000 – 2005	Associate Dean, College of Science University of Notre Dame
2001 – 2006	Hematologist – Oncologist Northern Indiana Oncology Associates South Bend, IN
2005 – 2009	Director, Walther Cancer Research Center Adjunct Professor of Biochemistry Department of Chemistry and Biochemistry University of Notre Dame
2005 – 2011	Professor of Medicine Assistant Dean and Director Indiana University School of Medicine South Bend Adjunct Professor of Biochemistry Department of Chemistry and Biochemistry University of Notre Dame
2010 – 2013	Clinical Director, Harper Cancer Research Institute Indiana University School of Medicine South Bend

2012 – 2014	Professor of Medicine Associate Dean and Director Indiana University School of Medicine South Bend Adjunct Professor of Biochemistry Department of Chemistry and Biochemistry University of Notre Dame
2013- 2014	Medical Director Navari Student Outreach Clinic Indiana University School of Medicine South Bend
2014 – 2015	Director, Cancer Care Program Eastern Europe World Health Organization
2014 – 2015	Clinical Professor of Medicine Indiana University School of Medicine South Bend
2014 - Present	President, South Bend Medical Services Corporation South Bend, IN
2015 – 2016	Director, Cancer Care Program Central and South America World Health Organization
2016 – 2020	Professor of Medicine Division of Hematology – Oncology University of Alabama Birmingham (UAB) School of Medicine
2017 – 2020	Hematologist – Oncologist Birmingham VA Medical Center
2017 – 2020	Senior Scientist, Experimental Therapeutics Program UAB Comprehensive Cancer Center
2017 – 2020	Clinical Skills Scholar University of Alabama Birmingham School of Medicine
2020 – Present	Executive Director Cancer Care Program, Central and South America World Health Organization

2020 – 2022	Hematologist Oncologist Simon Williamson Clinic Birmingham, AL 35211
2020-2022	Locums Coverage, Monthly Weekend Coverage Oncology Associates of West Alabama DCH Hospital. Tuscaloosa, AL
1/2023 – 12/2023	Locums Coverage Cos Bay Cancer Center Cos Bay, Oregon
1/2024 – Present	Locums Coverage Hematology Oncology Associates of Alabama Gadsden, AL
8/2024 – Present	Hematologist Oncologist Oncology Clinic Cooper Green Health – UAB Birmingham, AL

BOARD CERTIFICATION AND LICENSING:

1978	Diplomate, National Board of Medical Examiners
1978	State of Alabama Medical License (#8424)
1981	Diplomate, American Board of Internal Medicine
1981	State of Washington Medical License
1983	Diplomate, Subspecialty Board of Medical Oncology
1998	State of Indiana Medical License
2016	State of Mississippi Medical License
2020	State of Missouri Medical License

PROFESSIONAL AND HONORARY SOCIETIES:

1974 - Present	Alpha Sigma Chi (Leadership Honorary) American Association for Advancement of Science, Member American College of Physicians, Member
1977 - Present	American Federation for Clinical Research, Member American Institute of Chemical Engineers, Associate Member American Chemical Society, Member
1968 - Present	Sigma Xi (Research Honorary), Member

1972 - 1973	President, Hollins College Sigma Xi Club
1966	Tau Beta Pi (Engineering Honorary), Member
	Virginia Academy of Science, Member
1983 – Present	Alabama Society of Clinical Oncology
	(President, 1986-88)
1983 – Present	American Society of Clinical Oncology, Member

HONORS

1966	Cum Laude Graduate, University of Notre Dame
1966 - 1969	NDEA Title IV Fellowship, University of Virginia,
1969 - 1970	Ethyl Corporation Fellowship, University of Virginia,
1974	A. D. Williams Research Fellowship, Medical College of Virginia
1976	L. Beverly Chaney Leadership Award, Medical College of Virginia
1977	School of Medicine Research Prize - First Place, Medical College of Virginia
1977 - 1978	Ben Friedman Award - Excellence in Teaching by an Intern,
	University of Alabama, Birmingham
1979 - 1980	Ben Friedman Award - Excellence in Teaching by a Resident,
	University of Alabama, Birmingham
1981 - 1982	Clinical Fellowship, American Cancer Society
1985	Outstanding Physician Award for Clinical Instruction,
	Baptist Medical Center - Princeton
1997	Fellow, American College of Physicians
2006	Fellow, John J. Reilly Center for Science, Technology, and Values,
	University of Notre Dame
2009	Emil T. Hofmann Lecturer, University of Notre Dame
2014	Sagamore of the Wabash Award, Leadership and Service
	Governor Michael Pence, State of Indiana
2014	Navari-Harper Scholarship
	Indiana University School of Medicine South Bend
2014	Navari Student Outreach Clinic
	Indiana University School of Medicine South Bend
2014	Honoree, 2014 Medicine Ball
	Indiana University School of Medicine South Bend
2015	Token of Appreciation from Medical Students Award
	University of Michigan Medical School
2017	Clinical Skills Scholar
	University of Alabama School of Medicine

EDITORIAL BOARDS

2002 – Present	*Current Drug Targets*, Associate Editor
2004 - 2014	National Cancer Institute Supportive Care Editorial Board
2016- Present	Expert Review of Quality of Life in Cancer Care
2016- Present	Cancer Management and Research, Associate Editor

PUBLICATIONS:

1. Navari, R.M. and Gainer, J.L.: Prediction of the sigma effect in blood flow, 1968. Biorheology 5: 237-239.

2. Navari, R.M., Gainer, J.L., and Updike, O.L.: Blood flow modeling with microcapsular suspensions, 1969. Ind. Eng. Chem. Fund 8: 615-624.

3. Navari, R.M., Gainer, J.L., and Hall, K.R.: Effect of plasma constituents on oxygen diffusivity, 1970. In: Blood Oxygenation, Hershey, D. (ed.). New York: Plenum Press, pp 243-261.

4. Navari, R.M., Gainer, J.L., and Hall, K.R.: A predictive theory for diffusion in polymer and protein solutions, 1971. Am. Inst. Chem. Eng. J. 10: 1028-1036.

5. Navari, R.M., Gainer. J.L., and Hall, K.R.: Transport in human plasma, 1971. Aerospace Med. 42: 1123-1125.

6. Navari, R.M. and Gainer, J.L.: Effect of red cell deformability on blood viscosity, 1972. Rheology of Biological Systems, Gabelnick, H. and Litt, M. (eds), Philadelphia: C.C. Thomas, Chap. 3.

7. Navari, R.M.: Hematology for undergraduates, 1972. J. College Science Teaching 2: 26-33.

8. Bryant, S.C. and Navari, R.M.: Effect of plasma proteins on oxygen diffusion in the pulmonary capillaries, 1974. Microvascular Res. 7: 1-11.

9. Navari, R.M.: Laboratory experiments using nicotine, 1974. J. Chem. Education 51: 748-750.

10. Navari, R.M. and Prodouz, T.N.: Effects of vitamins and E on rat tissue lipids, 1975. Nutrition Reports International 11: 17-28.

11. Rosenblum, W.I., Navari, R.M., Levasseur, J.R., and Patterson, J.L., Jr.: In vitro depression of tissue oxygen uptake by liquid fluorocarbon prepared as artificial blood, 1977. Proc. Soc. Exp. Med. Biol. 154: 346-350

12. Navari, R.M., Rosenblum, W.I., Kontos, H.A., and Patterson, J.L., Jr.: Mass transfer properties of gases in fluorocarbon emulsions, 1977. Res. Exp. Med. 170: 169-180.

13. Navari, R.M., Rosenblum, W.I., Kontos, H.A., Levasseur, J.E., and Patterson, J.L., Jr.: Effects of perfluorochemical emulsions prepared as artificial blood on the in vitro oxygen consumption of rat pulmonary bronchioles, 1977. Proceedings of Symposium on Research on Perfluoro-chemicals in Medicine and Biology, Novakova, V. (ed.). Stockholm: Karolinska Institute.

14. Navari, R.M. and Patterson, J.L., Jr.: Inhibition of rat bronchiolar oxygen consumption by plasma proteins, 1978. J. Appl. Physiol. Respirat. Environ. Exercise Physiol. 44: 659-664.

15. Navari, R.M., Wei, E.P., Kontos, J.A., and Patterson, J.L., Jr.: Comparison of the open skull and cranial window preparations in the study of the cerebral microcirculation, 1978. Microvascular Res. 16: 304-315.

16. Kontos, J.A., Wei, E.P., Navari, R.M., Levasseur, J.E., Rosenblum, W. I., and Patterson, J.L., Jr.: Responses of cerebral arteries and arterioles to acute hypotension and hypertension, 1978. Am. J. Physiol. 234: H371-H383.

17. Kontos, H.A., Wei, E.P., Raper, A.J., Rosenblum, W.I., Navari, R.M., and Patterson, J.L., Jr.: Role of tissue hypoxia in local regulation of cerebral microcirculation, 1978. Am. J. Physiol. 234: H582-H591.

18. Navari, R.M., Wei, E.P., Kontos, H.A., and Patterson, J.L., Jr.: Oxygen consumption of pial arterioles, 1979. Am. J. Physiol. 236: H151-H156.

19. Wei, E.P., Dietrich, W.D., Povlishock, J.T., Navari, R.M., and Kontos, H.A.: Functional,morphologic and metabolic abnormalities of the cerebral microcirculation after concussive brain injury in cats, 1980. Circ. Res. 46: 37-47.

20. Kontos, H.A., Wei, E.P., Dietrich, W.D., Navari, R.M., Povlishock, J.T., Ghatak, N.R., Ellis, E.F., and Patterson, J.L., Jr.: Mechanism of cerebral arteriolar abnormalities after acute hypertension, 1981. Am. J. Physiol. 240: H511-H527.

21. Navari, R.M., Ploth, D.W., and Tatum, R.K.: Renal adenocarcinoma associated with multiple simple cysts, 1981. JAMA 246: 1808-1809.

22. Navari, R.M. and Sheehy, T.W.: Routine endoscopy in upper gastrointestinal bleeding, 1982. N. Engl. J. Med. 306: 870.

23. Navari, R.M., Sheehy, T.W., McLean, B.K., and Sutton, F.D.: The peripheral blood in heat

stroke, 1983. Alabama J. Med Sci 20: 137-140.

24. Navari, R.M., Carter, J., and Hillman, R.S.: Bone marrow necrosis in acute leukemia, 1983. Acta Haemat. 69: 158-163.

25. Navari, R.M., Sharma, P., Deeg, H.J., McDonald, G.B., and Thomas, E.D.: Pneumatosis cystoides intestinalis following allogeneic marrow transplantation, 1983. Clin. Transplant. Proc. 15: 1720-1724.

26. Navari, R.M., Sullivan, K.M., Springmeyer, S.C., Siegel, M.C., Meyers, J.D., Buckner, C.D., Sanders, J.E., Stewart, P.S., Clift, R.A., Fefer, A., Storb, R., and Thomas E.D.: Mycobacterial infections in marrow transplant patients, 1983. Transplantation, 36: 509-513.

27. Navari, R.M., Buckner, C.D., Clift, R.A., and Coleman, K.M.: Bone marrow transplantation, 1984. Laboratory Medicine, 15: 245-250.

28. Navari, R.M., Buckner, C.D., Clift, R.A., Storb, R., Sanders, J.E., Stewart P., Sullivan K.M., Williams, B., Counts, G.W., Meyers, J.D., and Thomas, E.D.: Prophylaxis of infection in patients with aplastic anemia receiving allogeneic marrow transplants, 1984. Am. J. Med., 76: 564-572.

29. Sheehy, T.W. and Navari, R.M: Hypothermia, 1984. Alabama J. Med. Sci. 21: 374 - 381.

30. Clift, R.A., Buckner, C.D., and Navari, R.M.: Marrow Transplantation, 1985. In: Comprehensive Textbook of Oncology, Moossa, A.R., Robson, M.C., and Schimpff, S.C. (eds.), Baltimore: Williams and Wilkins, Ch. 27.

31. Navari, R.M. and Sheehy, T.W.: Hypothermia, 1986. In: The Practice of Geriatrics. Calkins, E., Davis, P.J., Ford, A.M. (eds.) Philadelphia: W.B. Saunders Company, Ch. 28.

32. Witherspoon, R.P., Navari, R.M., Storb, R., Sullivan, K.M., Doney, K., Beatty, P., Lum, L.G., and Thomas, E.D.: Treatment of Marrow Graft Recipients with Thymopentin, 1987. Bone Marrow Transplantation, 1: 365-371.

33. Navari, R.M.: High Dose Chemotherapy and Autologous Bone Marrow Infusion for Malignancies Refractory to Conventional Treatment, 1987. Bulletin of Clinical Services - Baptist Medical Center Princeton, 1(1): 15-21.

34. Navari, R.M.: Effective Antiemetic Therapy for the Control of Chemotherapy-Induced Emesis, 1987: Bulletin of Clinical Services - Baptist Medical Center Princeton, 1(2): 15-21.

35. Navari, R.M.: Comparison of Intermittent and Continuous Infusion Metoclopramide for the Control of Acute Nausea in Patients Receiving Cisplatin Chemotherapy, 1989. J. Clinical

Oncology, 7: 943-946.

36. Navari, R.M.: Primary Central Nervous System Malignant Lymphoma, 1989: Bulletin of Clinical Services - Baptist Medical Center Princeton 3(1): 2-9.

37. Navari, R.M.: The Ethics of Organ Transplantation, 1989. Notre Dame Science Quarterly, 27: 17-21.

38. Santen, R.J., Demers, L.M., Lynch, J., Harvey, H., Lipton, A., Mulagha, M., Hanagan, J., Garber, J.E., Henderson, I.C., Navari, R.M. and Miller, A.A.: Specificity of Low Dose Fadrozole Hydrochloride (CGS 16949A) as an Aromatase Inhibitor. J. Clin. Endocrinol. Metab 73: 99-106, 1991.

39. Beck,T.M.,Hesketh,P.J., Madajewicz, S., Navari,R.M., Pendergrass, K., Lester, E.P.,Kish, J.A.,Murphy, W.K., Hainsworth, J.D., Gandara, D.R., Bricker, L.J., Keller, A.M., Mortimer, J., Galvin, D.V.,House, K.W. and Bryson, J.C.: Stratified, Randomized, Double-Blind Comparison of Intravenous Ondansetron Administered as a Multiple-Dose Regimen Versus Two Single-Dose Regimens in the Prevention of Cisplatin-Induced Nausea and Vomiting. J. Clin. Oncol. 10: 1969-1975, 1992.

40. Richards, E.W., Long, C.L., Nelson, K.M., Pinkston, J.A., Navari, R.M., Geiger, J.W., Gandy, R.E., Blakemore, W.S.: Glucose Metabolism in Advanced Lung Cancer Patients. Nutrition 8: 245-251, 1992.

41. Richards, E.W., Long, C.L., Nelson, K.M., Tohver, O.K., Pinkston, J.A., Navari, R.M. and Blakemore, W.S.: Protein Turnover in Advanced Lung Cancer Patients. Metabolism, 42: 291-296, 1993.

42. Navari, R.M., Province, W.S., Perrine, G.M., Kilgore, J.R.: Comparison of Intermittent Ondansetron Versus Continuous Infusion Metoclopramide Used with Standard Combination Antiemetics in Control of Acute Nausea Induced by Cisplatin Chemotherapy. Cancer, 72: 583-586, 1993.

43. Navari, R.M., Kaplan, H.G., Grant, R.J., Grunberg, S.M., Palmer, R., Fitts, D.: Efficacy and Safety of Granisetron, A Selective 5 -Hydroxytryptamine - 3 Receptor Antagonist, in the Prevention of Nausea and Vomiting Induced by High Dose Cisplatin. J. Clin. Oncol., 12: 2204-2210, 1994.

44. Gucalp, R., Theriault, R., Gill, I., Madajewicz, S., Chapman, R., Navari, R.M., Ahmann, F., Zelenakas, K., Hefferman, M., Knight, R.D.: Treatment of Cancer Associated Hypercalcemia. Arch Intern Med., 154: 1935-44, 1994.

45. Navari, R.M., Gandara, D., Hesketh, P., et al: A Comparative Clinical Trial of Granisetron and Ondansetron in the Prophylaxis of Cisplatin-Induced Emesis. J. Clin. Oncol. 13:1242-1248, 1995.

46. Navari, R.M., Madajewicz, S., Anderson, N. et al.: Oral Ondansetron for the Control of Cisplatin Induced Delayed Emesis: A Large, Multi-Center, Double Blind, Randomized Comparative Trial of Ondansetron Versus Placebo.
J. Clin. Oncol. 13: 2408-16, 1995.

47. Navari, R.M.: Is Oral Ondansetron Really Efficacious in the control of Cis-Platinum - Induced Delayed Emesis?
J. Clin Oncol. 14: 1401-2, 1996

48. Miller, A.A., Lipton, A., Henderson, I.C., Navari, R.M., et al: Fadrozole Hydrochloride in Postmenopausal Patients with Metastatic Breast Carcinoma. Cancer 78: 789-93, 1996.

49. Hesketh, P., Navari, R.M., Grote, T., et al: Double-Blind, Randomized Comparison of the Antiemetic Efficacy of Intravenous Dolasetron Mesylate and Intravenous Ondansetron in the Prevention of Acute Cisplatin-Induced Emesis in Patients With Cancer. J. Clin. Oncol. 14: 2242-2249, 1996.

50. Pater, J.L., Lofters, W.S., Zee, B., Dempsey, E., Walde, D., Moquin, J.P., Wilson, K., Hoskins, P., Guevin, R.M., Verma, S. Navari, R.M., et al: The Role of the 5-HT_3 Antagonists Ondansetron and Dolasetron in the Control of Delayed Onset Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy. Ann. Oncol. 8: 181-85, 1997.

51. Perez, E.A., Navari, R.M., Kaplan, H.G., et al: Efficacy and Safety of Different Doses of Granisetron for the Prophylaxis of Cisplatin-Induced Emesis. Support Care Cancer 5: 31-37, 1997.

52. Kris, M.G., Pendergrass, K.B., Navari, R.M., et al: Prevention of Acute Emesis Following High-Dose Cisplatin with the Combination of Oral Dolasetron and Dexamethasone. J. Clin. Oncol., 15:2135-38, 1997.

53. Beck TM, York M, Chang A, Navari RM, et al: Oral Ondansetron 8 mg Twice Daily Is as Effective as 8 mg Three Times Daily in the Prevention of Nausea and Vomiting Associated with Moderately Emetogenic Cancer Chemotherapy. Cancer Invest. 15:297-303, 1997.

54. Lofters WS, Pater JL, Zee B, Dempsey E, Walde D, Moquin J, Wilson K, Hoskins P, Guevin RM, Verma S, Navari RM, et al: Phase III Double-Blind Comparison of Dolasetron Mesylate and Ondansetron and an evaluation of the Additive Role of Dexamethasone in the Prevention of Acute and Delayed Nausea and Vomiting Due to Moderately Emetogenic

Chemotherapy. J. Clin. Oncol. 15:2966-73, 1997.

55. Gralla R.J., Navari R.M., Hesketh P.J., et al. Single-Dose Oral Granisetron Has Equivalent Antiemetic Efficacy to Intravenous Ondansetron for Highly Emetogenic Cisplatin-Based Chemotherapy. J. Clin Oncol. 16:1568-1573, 1998.

56. Navari RM. The Role of Neurokinin-1 Antagonists in Reducing Chemotherapy Induced Emesis: Current Status. Current Advances in Emesis Control, September, 1998.

57. Navari RM, Reinhardt RR, Gralla RJ et al. Reduction of cisplatin-induced emesis by a neurokinin-1 receptor antagonist. N. Engl. J. Med. 340: 190-5, 1999.

58. Navari RM, Carides AD, Gertz BJ Prevention of cisplatin-induced emesis by a neurokinin-1 receptor antagonist. N.Engl. J. Med. 340: 1926-7, 1999.

59. Navari RM. Use of placebos in delayed-emesis studies. J. Clin. Oncol. 17:1648-9, 1999.

60. Navari RM, Horner-Catt J, Siegler M. A prisoner with chronic myelogenous leukemia. Bone Marrow Transplantation, 24:1037-39, 1999.

61. Navari RM, Stocking CA, Siegler M. Patient Decisions Concerning Palliative Care. Proceedings of the Xth International Association of Catholic Medical Schools Congress, J. Cousins, ed., Lille, France, 2000.

62. Navari RM, Stocking CA, Siegler M. Preferences of Patients With Advanced Cancer for Hospice Care. JAMA 284:2449, 2000.

63. Anderson AK, Nemecek JE, Navari RM. International Study in Premedical Education. Academic Medicine, 76: 1158, 2001.

64. Harris L, Batist G, Belt R, Rovira D, Navari R, Garrett T, Azarnia N, Welles L. Winer E. Liposome-encapsulated Doxorubicin Compared to Conventional Doxorubicin in a Randomized Multicenter Trial as First-Line Therapy of Metastatic Breast Cancer. Cancer, 87: 25-33, 2002.

65. Navari RM. Physicians Tackle Ethical Issues in Palliative Care. Oncologistics, 1:17, 2002.

66. Van Belle S, Lichinitser MR, Navari RM, et. al. Prevention of Cisplatin-Induced Acute and Delayed Emesis by the Selective Neurokinin-1 Antagonists, L-758,298 and MK-869. Cancer 94:3032-41, 2002.

67. Navari RM. Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis:

preclinical data. Current Advances in Emesis Control 2:3-6, 2002.

68. White PH, Kuhlenschmidt, HL, Vancura BG, Navari RM. Antimicrobial use in patients with advanced cancer receiving hospice care. J Pain Symptom Management, 25: 438-443, 2003.

69. Navari RM. Infections in Patients with Advanced Cancer. in Handbook of Advanced Cancer, MJ Fisch, E Bruera (eds), pp. 444-459, Cambridge University Press, New York, 2003.

70. Navari RM, Koeller JM. Electrocardiographic Effects of the 5-Hydroxytryptamine-3 Receptor Anatogonists. Annals of Pharmacotherapy, 37: 1276-1286, 2003.

71. Navari RM. Caring for patients with chemotherapy-induced nausea and vomiting: a paradigm shift in treatment options. SCAN 3: 2-17, 2003.

72. Navari RM. Chemotherapy-induced nausea and vomiting: New treatment options. Contemporary Oncology 2: 1-10, 2003.

73. Navari RM. Pathogenesis based treatment of chemotherapy-induced nausea and vomiting: Two new agents. J Supportive Oncology, 1: 89-103, 2003.

74. Navari RM, Koeller JM. Cardiovascular effects of the 5-Hydroxytryptamine-3 receptor antagonists. Annals of Pharmacotherapy 37: 1918-19, 2003.

75. Navari RM "Inhibiting substance P pathway for prevention of chemotherapy-induced emesis: Preclinical data, clinical trials of neurokinin-1 receptor antagonists" in Supportive Cancer Therapy 2004; 1:89-96.

76. Navari RM. Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis: summary of clinical trials. Cancer Investigation 22: 569-576, 2004.

77. Passik S, Navari RM, Loehrer PJ et al. A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients receiving chemotherapy. Cancer Investigation, 22: 383-388, 2004.

78. Suckow MA, Gutierrez LS, Risatti CA, Wolter WR, Taylor RE, Pollard M, Navari RM, Castellino FJ, Paoni NF The anti-ischemic agent ranolazine promotes the development of intestinal tumors in APC Min Mice, Cancer Letters, 209: 165-169, 2004.

79. Navari RM Aprepitant – A neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther 4:715-724, 2004.

80. Navari RM, Einhorn LH, Passik SD et al. A phase II trial of olanzapine for the prevention of chemotherapy induced nausea and vomiting. Supportive Care Cancer, 13: 529 - 534, 2005.

81. Navari RM Advances in the treatment of chemotherapy-induced nausea and vomiting. Hospital Pharmacy Europe, 20: 37-40, 2005.

82. Reinbolt RE, Shenk AM, White PH, Navari RM. Symptomatic Treatment of Infections in Patients with Advanced Cancer Receiving Hospice Care. J Pain Symptom Management, 30: 175-182, 2005.

83. Navari RM. Treating depression in people with cancer. Coping, November/December: 8-9, 2005.

84. Navari RM, Province PS. Emerging Drugs for Chemotherapy-induced Emesis. Expert Opin Emerging Drugs, 11:137-151, 2006.

85. Busquets L, Guillen H, DeFord ME, Suckow MA, Navari RM, Castellino FJ, Prorok M Cathepsin E is a Specific Marker of Dysplasia in $APC^{Min/+}$ Mouse Intestine. Tumor Biol 27: 36-42, 2006.

86. Navari, RM Ondansetron, prochlorperazine, and dexamethasone have similar effects on prevention of delayed chemotherapy-induced nausea and vomiting- commentary. Cancer Treatment Reviews 32 (1): 50-54, 2006.

87. Province PS, Navari RM Infections. Chapter 79, in Textbook of Palliative Medicine E Bruera, IJ Higginson, C Ripamonti, CF von Gunten (eds), Arnold Publishers, London, 2006.

88. Navari RM Palonosetron: A second generation 5-Hydroxytryptamine 3 (5-HT3) receptor antagonist. Future Oncology, 2: 591-602, 2006.

89. Rubenstein EB, Slusher BS, Rojas C, Navari RM. New approaches to chemotherapy-induced nausea and vomiting: From neuropharmacology to clinical investigations. Cancer J 12: 342-348, 2006.

90. Navari RM. Prevention of emesis from multiple-day chemotherapy regimens. JNCCN, 5: 51-59, 2007.

91. Navari RM. Review of Updated Antiemetic Guidelines for Chemotherapy-Induced Nausea and Vomiting. Community Oncology, 4: 1s-11s, 2007.

92. Navari RM, Einhorn LH, Loehrer PJ et al. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy induced nausea and vomiting. Supportive Care Cancer, 15: 1285 - 1291, 2007.

93. Navari RM End of life decisions by adults with cancer: Role of religious practices and spiritual beliefs. in "Faith and Healing", T. Merluzzi, NC Hvidt (eds), in press, 2008.

94. Navari, RM Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Expert Opin Invest Drugs, 16: 1977-1985, 2007.

95. Navari RM, Brenner MC, Wilson MN Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Res Treat 112: 197-201, 2008.

96. Navari RM Casopitant: drug profile. The Investigational Drugs Database: Drug Report www.iddb3.com, July, 2008.

97. Navari RM Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and antinausea activities. Curr Opin Investig Drugs, 9: 774-785, 2008.

98. Navari RM Fosaprepitant for the prevention of chemotherapy induced nausea and Vomiting. . Expert Rev Anticancer Ther 8: 1733-1742, 2008.

99. Navari RM Prevention and treatment of chemotherapy-induced nausea and vomiting in the setting of moderately emetogenic chemotherapy. www.medscape.com/viewprogram/17173, August, 2008.

100. Navari RM Antiemetic control:Toward a new standard of care for emetogenic chemotherapy. Expert Rev Pharmacotherapy 10: 629-644, 2009.

101. Navari RM Pharmacological management of chemotherapy-induced nausea and vomiting. Drugs 69: 515-533, 2009.

102. Navari RM Palonosetron: a second generation 5-Hydroxytryptamine-3 receptor antagonist. Expert Opin Drug Metabolism Toxicity 5: 1577-1586, 2009.

103. Navari RM Current treatment options for managing chemotherapy-induced nausea and vomiting (CINV). Contemporary Oncology 1:39-47, 2009.

104. Navari, RM Brenner MC Treatment of cancer-related anorexia with megestrol acetate and olanzapine. Support Care Cancer, 18:951-956, 2010.

105. Navari RM Palonosetron for the prevention of chemotherapy-induced nausea and vomiting. Cancer Management Res. 1:167-176, 2009.

106. Navari RM Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer. Future Oncology, 6:1073-84, 2010.

107. Castellino FJ, Donahue DL, Navari RM et al. An accompanying genetic severe deficiency of tissue factor protects mice with a protein C deficiency from lethal endotoxemia. Blood, 117: 283-289, 2011.

108. Navari RM, Province PS, Passik, SD Management of Nausea and Vomiting in Cancer Patients. in Cancer Management in Man: Biological Response Modifiers, Chemotherapy, Biological therapy, Hyperthermia, and Supporting Measures B Minev, (ed.), pp 453-71, Springer Academic Publishers, N.Y., 2011.

109. Navari RM, Gray SE, Kerr AC Olanzapine versus aprepitant for the prevention of chemotherapy induced nausea and vomiting (CINV): A randomized phase III trial. J Supp Oncol, 9: 188-195, 2011.

110. Walsh M, Thomas SG, Howard JC, Evans E, Guyer K, Medvecz, Swearingen A, Navari RM, Ploplis V, Castellino FJ. Blood component therapy in trauma guided with the Utilization of the perfusionist and thromboelastography. J ExtraCorporeal Technology, 43: 162-67, 2011.

111. Navari RM Treatment of Chemotherapy Induced Nausea. Community Oncology, 9: 20-26, 2012.

112. Kiziltepe T, Ashley JD, Stefanick JF, Qi YM, Alves NJ, Handlogten MW, Suckow MA, Navari RM, Bilgicer B. VLA4 targeting multifunctional nanoparticles overcome drug Resistance and inhibit tumor growth in multiple myeloma. Blood Cancer J, 2: 64-69, 2012.

113. Navari RM How do I treat chemotherapy-induced nausea and vomiting? Oncology Times, 34: 16-19, 2012.

114. Navari RM, Nagy, CK, Gray SE. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Support Care Cancer, 21:1655-1663, 2013.

115. Navari RM Management of chemotherapy-induced nausea and vomiting: Focus on newer agents and new uses for older agents. Drugs, 73:249-262, 2013.

116. Alves NJ, Champion MM, Stefanick JF, Handlogten MW, Demetri MT, Shi Y, Shaw BF, Navari RM, Kiziltepe T, Bilgicer B. Selective photocrosslinking of functional ligands to antibodies via the conserved nucleoside binding site. Biomaterials, 34:5700-5710, 2013.

117. Navari RM The current status of the use of palonosetron. Expert Opin Pharmacother, 14:1281-1284, 2013.

118. Navari RM A review of the prevention of nausea and vomiting induced by chemotherapy. European Oncology and Haematology, 9: 51-55, 2013.

119. Navari RM Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting. European J Pharm, 722:180-186, 2014.

120. Navari RM Clinical Trial Data in Chemotherapy-Induced Nausea and Vomiting. Clinical Advances in Hematology & Oncology, 12:5-8, 2014.

121. Navari RM, Green C, Haney ML, Roach NL Infections in Palliative Care. Chapter 77, pp 791-96, in Textbook of Palliative Medicine and Supportive Care E Bruera, IJ Higginson, CF von Gunten, T Morita (eds), Arnold Publishers, London, 2015.

122. Navari RM Palonosetron for the treatment of chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother, 15:2599-2608, 2014.

123. Navari RM Profile of netupitant/palonosetron fixed dose combination (NEPA) and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV). Drug Design, Development and Therapy, 9: 155-161, 2015.

124. Navari RM Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting. Biomed Res International, in press, 2015.

125. Navari RM Management of Nausea and Vomiting, Chapter 35, In Cancer Management: A Multidisciplinary Approach, Oncology, 2015.

126. Schwartzberg L, Modiano M, Rapoport B, Chasen M, Gridelli C, Urban L, Poma A, Arora S, Navari RM, Schnadig I Safety and Efficacy Assessment of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Following Administration of Moderately

Emetogenic Chemotherapy in Cancer Patients in a Randomised Phase 3 Trial. Lancet Oncol, 16:1071-1078, 2015.

127. Rapoport B, Chasen M, Gridelli C, Urban L, Modiano M, Schnadig I, Poma A, Arora, Kansra V, Schwartzberg L, Navari RM Safety and Efficacy Assessment of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Following Administration of Cisplatin-Based Highly Emetogenic Chemotherapy in Cancer Patients in Two Randomised Phase 3 Trials. Lancet Oncol, 16: 1079-1089, 2015.

128. Navari RM 5-HT3 Receptors as Important Mediators of Nausea and Vomiting due to chemotherapy. Biochem Biophys Acta -Biomembranes 1848: 2738-2746, 2015. DOI information: 10.1016/j.bbamem.2015.03.020

129. Navari RM Rolapitant for the treatment of chemotherapy induced nausea and vomiting. Expert Rev Anticancer Therapy, 15: 1127-1133, 2015.

130. Chow R, Chiu L, Navari RM et al, Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in Phase I and II studies: a systematic review. Support Care Cancer 24:1001-1008, 2016.

131. Navari RM Chemotherapy-Induced Nausea and Vomiting: Molecular Mechanisms and Clinical Approaches. Chapter 37, pp. 779-804, in International Manual of Oncology Practice, RA de Mello, A Tavares, G Mountzios eds., Springer, Switzerland, 2015.

132. Chiu L, Chow R, Popovic M, Navari RM, et al. Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis. Supportive Care Cancer, 24:2381-2392, 2016.

133. Navari RM, editor," Management of Chemotherapy-Induced Nausea and Vomiting: New Agents and New Uses of Current Agents", Springer International Publishing, Switzerland, 2016.

134. Navari RM, Aapro M Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting. New Engl J Med, 374:1356-1367, 2016.

135. Rapoport B, Schwartzberg L, Chasen M, Powers D, Arora S, Navari RM, et al. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of moderately or highly emetogenic chemotherapy. European J Cancer, 57: 23-30, 2016.

136. Navari RM, Nagy CK, Le-Rademacher, JG, Loprinzi CL Olanzapine versus fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving concurrent chemotherapy radiation therapy: a randomized, double-blind, phase III trial. J Comm Supp Oncol. 14: 141-147, 2016.

137. Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, Dietrich L, Biggs D, Lafky JM, Loprinzi CL Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. New Engl J Med, 375:134-142, 2016.

138. Navari RM, Rapaport BL, editors, "Fast Facts: Chemotherapy-Induced Nausea and Vomiting", Health Press Limited, Oxford, UK, 2016.

139. Navari RM The safety and efficacy of NEPA (netupitant + palonosetron) in the treatment of chemotherapy-induced nausea and vomiting. Expert Rev Quality Cancer Care, 1: 263-268, 2016.

140. Navari RM Should behavioral therapy be used as the primary treatment to control Anticipatory vomiting? HemeOnc Today, 17:13, 2016.

141. Herrstedt J, Roila F, Warr D, Celio L, Navari RM et al. 2016 MASCC/ESMO consensus recommendations for the prevention of nausea and vomiting following high emetic risk chemotherapy. Support Care Cancer 25: 277-288, 2017.

142. Chasen M, Urban L, Schnadig I, Rapoport B, Powers D, Arora S, Navari RM et al. Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy. Support Care Cancer 25: 85-92, 2017.

143. Navari RM The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Drug Saf, 15:343-356, 2016.

144. Navari RM Rolapitant hydrochloride: prophylactic treatment for chemotherapy-induced nausea and vomiting. Drugs of Today, 52:431-438, 2016.

145. Navari RM, Loprinzi CL Olanzapine for chemotherapy-induced nausea and vomiting. New Engl J Med 375: 1395-1396, 2016.

146. Einhorn LH, Rapoport B, Navari RM et al. 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer 25: 303-308, 2017.

147. Navari R. Management of nausea and vomiting. In: Haller DG, Wagman LD, Camphausen KA, Hoskins WJ, editors. Cancer management: a multidisciplinary approach. Norwalk, CT:

UBM Medica; 2015. http://www.cancernetwork.com/cancer-management/management-nausea-and-vomiting.

148. Navari RM Cancer patients at high risk for chemotherapy-induced nausea and vomiting - prediction assessments/tools. Expert Rev Quality Cancer Care 2:103-108, 2017.

149. Rapoport BL, Aapro M, Chasen M, Jordan K, Navari RM, Schnadig I, Schwartzberg L Recent developments in the clinical pharmacology of Rolapitant: subanalyses in specific populations. Drug Design Development Therapy 11:2621-2629, 2017.

150. Navari RM Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients. Pediatric Drugs 19: 213-222, 2017.

151. Navari RM Overview of the Neurokinin-1 Receptor Antagonists. Biotarget 1:8, 2017.

152. Ruddy KJ, Navari RM, Loprinzi CL Thalidomide: Rebirth of a gestational anti-emetic? J Clin Oncol 35:3523-3524, 2017.

153. Navari RM Chemotherapy-induced nausea and vomiting, in "International Manual of Oncology Practice (iMOP), 2nd edition, RA de Mello, editor, Springer, 2018.

154. Navari RM Antiemetics. In "Cancer Chemotherapy, Immunotherapy and Biotherapy", 6th edition, BA Chabner, DL Longo, editors, Ch 32, pp 587-601, Lippincott Williams & Wilkins, 2018.

155. Navari RM Advances in the Prevention of Chemotherapy Induced Nausea and Vomiting, Internal Medicine Rev 4, in press, 2018.

156. Navari RM Managing intractable nausea in patients with cancer. – What Works. Oncology Journal 32: 121-131, 2018.

157. Chow R, Warr DG, Navari RM et al. Efficacy and safety of 1-day versus 3-day dexamethasone for the prophylaxis of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis of randomized controlled trials. J Hosp Manage Health Policy 2;25, 2018.

158. Schwartzberg L, Roeland E, Andric Z, Kowalski D, Radic J, Voisin D, Rizzi D, Navari RM et al. Phase 3 safety study of intravenous NEPA, a novel fixed antiemetic combination of fosnetupitnat and palonosetron in patients receiving highly emetogenic chemotherapy. Annal Oncol 29:1535-1540, 2018.

159. Chow R, Warr DG, Navari RM et al. Should palonosetron be a preferred5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis. Supportive Care Cancer 26: 2519-2549, 2018.

160. Navari RM, Rapoport BL, Powers D et al. Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapy. Cancer Medicine 7:2943-2950, 2018.

161. Schwartzberg L, Navari RM Safety of Polysorbate 80 in the Oncology Setting. Adv Ther 35: 754-767, 2018.

162. Kim H, Morgan DE, Schexnailder P, Navari RM et al. Accurate therapeutic response assessment of pancreatic ductal adenocarcinoma using quantitative DCE-MRI with a point-of-care perfusion phantom: A pilot study. Investigative Radiology, in press, 2018.

163. Navari RM, Schwartzberg L Evolving role of neurokinin 1 receptor antagonists for chemotherapy-induced nausea and vomiting. OncoTargets Therapy 11:6459-6478, 2018.

164. Navari RM HTX-019: polysorbate 80– and synthetic surfactant–free neurokinin 1 receptor antagonist for CINV prophylaxis. Future Oncol 15:241-255, 2019.

165. Navari RM, Mosier MC Crossover safety study of aprepirant: 2-minute injection vs 30-minute infusion in cancer patients receiving emetogenic chemotherapy. OncoTargets Therapy 12:3277-3284, 2019.

166. Williams GR, Kenzik KM, Parham M, Rocque GB, McDonald A, Paluri R, Navari RM et al. Integrating geriatric assessment into routine gastrointestinal consultation: The Cancer and Aging Resilience. J Geriatric Oncol, in press, 2019.

167. Navari RM Chemotherapy Induced Nausea and Vomiting. In "International Manual of Oncology Practice" R. Andrade de Mello, ed. Chapter 48, Springer Nature, 2019.

168. Schwartzberg L, Navari RM, Clark-Snow R et al. Phase 3b safety and efficacy of intravenous NEPA for prevention of chemotherapy-induced nausea and vomiting in patients (CINV) with breast cancer receiving initial and repeat cycles of anthracycline/cyclophosphamide (AC) chemotherapy. Oncologist 24:1-9, 2019.

169. Chow R, Aapro M, Navari RM et al. Do we still need to study palonosetron for chemotherapy-indiced nausea and vomiting? A cumulative meta analysis. Critical Reviews in Oncology/Hematology 142: 164-186, 2019.

170. Navari RM Infections in Palliative Care. in Textbook of Palliative Medicine and Supportive

Care E Bruera, IJ Higginson, CF von Gunten, T Morita (eds), Arnold Publishers, London, in Press, 2020.

171. Navari RM The safety of rolapitant for the treatment of nausea and vomiting associated with Chemotherapy. Expert Opin Drug Saf. 18:1127-32, 2019.

172. Navari RM Nausea, vomiting in advanced cancer. Curr Treatment Options Oncol, in press, 2020.

173. Navari RM Safety Profile of HTX-019 Administered as an Intravenous Push in Patients with Cancer: A Retrospective Review. Exp Opin Drug Saf 19:205-210, 2020.

174. Navari RM, Ruddy KJ, LeBlanc TW, et al. Impact of the addition of carboplatin AUC ≥ 4 to antiemetic guidelines for triple antiemetic prophylaxis: A gap in quality of care, guideline adoption, and avoiding acute care. J Oncol Practice 16:e132-138, 2020.

175. Roeland EJ, Ruddy KJ, LeBlanc TW, Nipp R, Binder G, Sebastiani S, Potluri R, Schmerold LM, Papademetriou E, Navari RM. What the HEC? Clinician adherence to evidence-based antiemetic prophylaxis for highly emetogenic chemotherapy. JNCCN, in press, 2020.

176. Navari RM, Pywell CM, Le-Rademacher JG, White PH, Dodge AB, Albany C, Loprinzi CL A placebo controlled, randomized, double-blinded trial of olanzapine for the treatment of chronic nausea and/or vomiting, unrelated to chemotherapy/radiation. JAMA Oncology 6: 895-899 2020.

177. Navari RM, Loprinzi CL Olanzapine is an effective antiemetic agent. Annal Palliative Med, in press, 2020.

178. Navari RM, Roeland EJ Unscheduled hydrations: redefining complete response in chemotherapy-induced nausea and vomiting studies. Future Oncology, in press, 2020.

179. Loprinzi CL, Le-Rademacher JG, Navari RM The importance of a cause-based protocol to approach cancer-related nausea and vomiting. JAMA Oncol Published online September 17, 2020. doi:10.1001/jamaoncol.2020.3706.

180. Aapro M, Navari RM, Roeland E et al. Efficacy of intravenous NEPA, a fixed NK-1/5 HT-3 receptor antagonist combination, for the prevention of chemotherapy-induced nausea and voming (CINV) during cisplatin and anthrcycline cyclophosphamide based chemotherapy: A review of phase 3 studies. Critical Reviews in Oncology/Hematology.Published online November 13, 2020 doi.org/10/1016/j.critrevonc.2020.103143.

181. Navari RM, Ruddy KJ, LeBlanc TW et al. Avoidable acute care use associated with nausea and vomiting among patients receiving highly emetogenic chemotherapy or oxaliplatin. Oncologist. 26: 325-331, 2021

182. Chow R, Herrstedt J, Aapro M, Chin L, Lam H, Ptsic E, Lock M, DeAngelis C, Navari RM Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature. Support Care Cancer 29:3439-59, 2021.

183. Chow R, Chiu L, Herrstedt J, Aapro M, Lock M, DeAngelis C, Navari RM Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly-emetogenic chemotherapy (HEC) patients. Support Care Cancer, January, 2021.

184. Mukhopadhyay S, Premnath D, Navari RM et al. Low dose olanzapine, sedation and chemotherapy induced nausea & vomiting: A prospective, randomized, controlled study. Future Oncology, in press, 2021.

185. Navari RM, Binder G, Bonizzoni E, Clark-Snow R , Olivari S, Roeland EJ Single-dose NEPA versus 3-Day Aprepitant for Preventing Chemotherapy-Induced Nausea and Vomiting: A Pooled Analysis. Future Oncol, Apr 2021 https://doi.org/10.2217/fon-2021-0023.

186. Chow R, Navari RM, Terry B et al. Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis. Support Care Cancer doi.org/10.1007/s00520-021-06605-x; 06 October 2021.

187. Schwartzbweg l. Ruddy KJ, Navari RM et al. Avoidable acute care involving chemotherapy induced nausea and vomiting among patients with breast cancer receiving Anthracycline Cyclophosphamide with NEPA prophylaxis relative to other antiemeitics: An external control arm study. Frontiers in Oncology, in press, 2022.

188. Zelek L, Navari RM, Aapro A, Scotte F Single-dose NEPA versus an Aprepitant regimen for prevention of
chemotherapy-induced nausea and vomiting in patients receiving
moderately emetogenic chemotherapy. Supportive Care Cancer, submitted, 2022.

189. Navari RM, Binder G, Molasiotis A et al. Duration of chemotherapy induced nausea and vomiting (CINV)
as a predictor of recurrent CINV in later cycles. The Oncologist, in press, 2023.

190. Navari RM, Nelson WW, Shoaib s et al. Real-world treatment outcomes, Healthcare resource use, and costs associated with
antiemetics among cancer patients on cisplatin-based chemotherapy. Adv Ther, in press, 5/28/2023.

191 Navari RM, Le-Rademacher J, Smieliauskas F et al. Olanzapine with or without fosaprepitant for the prevention of chemotherapy-
induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). A phase III randomized,
double blind, placebo controlled trial. The Oncologist 28:722-729, 2023.

192. Zelek L, Navari RM, Aapro M, Scotte, F Single-dose NEPA versus an Aprepitant Regimen for Prevention of
Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy.
Cancer Medicine, in press, 2023

193. Schwartzber L, Navari RM, Ruddy KJ et al. Work Loss and Activity Impairment due to Extended Nausea and Vomiting in Patients
with Breast Cancer receiving CINV Prophylaxis. Support Care Cancer, in press, 2023.

194. Herrstedt J, Celio L, Hesketh PJ, Zhang L. Navari RM, et al. 2023 Updated MASCC/ESMO consensus recommendations: prevention
of nausea and vomiting following high-emetic-risk antineoplastic agents. Supp Care Cancer, in press, 2024.

195. Rapoport BL, Herrstedt J, Clark Snow R, Radhakrishnan V, Saito M, Navari RM, Smit T 2023 Updated MASCC/ESMO consensus
recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and

breakthrough nausea and vomiting. Supp Care Cancer, in press, 2024.

ABSTRACTS:

1. Navari, R.M., Updike, O.L., and Lilleleht, L.I.: A pseudo-blood suspension for flow studies, 1968. Va. J. Sci. 19: 192.

2. Navari, R.M., Gainer, J.L., and Updike, O.L.: Rheology of deformable particle suspensions, March 1969. American Institute of Chemical Engineers, National Meeting. New Orleans.

3. Navari, R.M., Gainer J.L., and Hall, K.R.: Mass transfer in biological solutions, May 1970. American Institute of Chemical Engineers, National Meeting, San Juan, Puerto Rico.

4. Navari, R.M. and Gainer, J.L.: Effect of erythrocyte deformability on whole blood viscosity, November 1971. American Institute of Chemical Engineers, Annual Meeting, San Francisco.

5. Navari, R.M., Gainer, J.L., and Hall, K.R.: Gas transfer in protein solutions, August 1972. American Institute of Chemical Engineers, National Meeting, Minneapolis.

6. Chin, J.M. and Navari, R.M.: Detection of drugs of abuse in urine, 1972. Va. J. Sci. 23: 126.

7. Bryant, S.C. and Navari, R.M.: Gaseous diffusion in the pulmonary capillaries, June 1973. American Institute of Chemical Engineers, National Meeting, Detroit.

8. Chin, J.M. and Navari, R.M.: Detection of drugs of abuse in urine with thin layer chromatography, June, 1973. American Institute of Chemical Engineers, National Meeting, Detroit.
9. Navari, R.M. and Bryant, S.C.: Oxygen transfer in the pulmonary capillaries, 1973. Va. J. Sci. 24: 170.

10. Navari, R.M., Rosenblum, W.I., Levasseur, J.E., and Patterson, J.L., Jr.: Apparent depression of oxygen consumption by fluorocarbon emulsions, 1975. Physiologist 18: 332.

11. Rosenblum, W.I., Navari, R.M., Levasseur, J.E., and Patterson, J.L., Jr.: Fluorocarbon effects on tissue oxygen consumption in vitro, 1976. Fed. Proc. 35: 933.

12. Navari, R.M. and Patterson, J.L., Jr.: Oxygen uptake of rate bronchioles, 1976. Fed. Proc. 35: 3439.

13. Kontos, H.A., Navari, R.M., Wei, E.P., and Patterson, J.L., Jr.: Oxygen consumption of pial arteries, 1977. Fed. Proc. 36: 1367.

14. Navari, R.M., Rosenblum, W.I., Kontos, H.A., and Patterson, J.L., Jr.: Solubility characteristics of oxygen and carbon dioxide in the fluorocarbons FC-80 and FC-47, 1977. Fed. Proc. 36: 1559.

15. Navari, R.M., Wei, E.P., Kontos, H.A., and Patterson, J.L. Jr.: Effects of induced acute hypertension on the oxygen consumption and responsiveness of cerebral arterioles, 1977. Clin. Res. 25: 241A.

16. Wei, E.P., Navari, R.M., Kontos, H.A., and Patterson, J.L., Jr.: Oxygen consumption and responsiveness of pial arteries following acute experimental brain injury, 197. Circulation 56(4): III, 43.

17. Wei, E.P., Navari, R.M., Kontos, H.A., and Patterson J.L., Jr.: Role of hypertension in microcirculatory responses to experimental head injury, 1978. Stroke 9: 102, IV-8.

18. Navari, R.M., Sheehy, T.W., and Sutton, F.D.: The peripheral blood in heat stroke, 1980. Clin. Res. 28: 826A.

19. Navari, R.M., Sirmon, M.D., Adolphson, C.A., and Durant, J.R.: Prevalence, diagnosis, and treatment of progressive multifocal leukoencephalopathy, Sept. 1982. Thirteenth International Cancer Congress, Seattle.

20. Navari, R.M., Buckner, C.D., Clift, R.A., Sullivan, K.M., and Storb, R.: Prophylaxis of infection in patients with aplastic anemia receiving allogeneic marrow transplants, 1983. ASCO 2: 332A.

21. Navari, R.M., Hennessey, B., Perrine, G.M.: Comparison of Antiemetics Prochlorperazine and Metoclopramide in Patients Receiving Doxorubicin Chemotherapy Regimens, 1986. ASCO 5: 1009.

22. Navari, R.M., Parrott, J.: Comparison of Intermittent and Continuous Infusion Metoclopramide for the Control of Nausea in Patients Receiving Cisplatin Chemotherapy, 1988. ASCO 7: 1090.

23. Santen, R.J., Demers, L., Lipton, A., Harvey, H.A., Hanagen, J., Mulagha, M., Navari, R.M.,

Henderson, I.C., Garber, J.E., Miller, A.A.: Phase II Study of the Potency and Specificity of a New Aromatase Inhibitor -CGS 16949A, 1989. American Soc. Clin. Invest., May Meeting, Washington, D.C.

24. Easterwood, T.R., Long, C.L., Nelson, K.M., Geiger, J.W., Blakemore, W.S., Pinkston, J.A., Navari, R.M.: Energy Expenditure and Nitrogen Losses in Lung Cancer, 1989. Fed. Am. Soc. Exp. Biol., 3: A-475.

25. Wayland, A.S., Nelson, K.M., Long, C.L., Blakemore, W.S., Pinkston, J.A., Navari, R.M.: Glucose Metabolism in Advanced Stage Lung Cancer, 1989. Fed. Am. Soc. Exp. Biol., 3: A-706.

26. Richards, E.W., Long, C.L., Nelson, K.M., Blakemore, W.S., Pinkston, J.A., Navari, R.M.: Effects of Advanced Lung Cancer on Glucose Metabolism, 1990. J. Pen. 14: 22S:92.

27. Richards, E.W., Long, C.L., Nelson, K.M., Blakemore, W.S., Pinkston, J.A., Navari, R.M.: Energy Expenditure and Nitrogen Losses in Lung Cancer Patients, 1990. Fed. Am. Soc. Exp. Biol. 4: A-5293.

28. Long, C.L., Richards, E.W., Nelson, K.M., Hoss, W.L., Blakemore, W.S., Pinkston, J.A., Navari, R.M.: Protein Metabolism in Advanced Lung Cancer, 1990. Fed. Am. Soc. Exp. Biol. 4: A-5292.

29. Harvey, H.A., Lipton, A., Santen, R.J., Demers, L., Henderson, I.C., Miller, A.A., Navari, R.M., Mulagha, M.T. and Hanagan, J.: Clinical Trials with the Aromatase Inhibitor CGS 16949A in Advanced Breast Cancer: the US Experience, 15th International Cancer Congress, Hamburg, August, 1990.

30. Beck, T.M., Madajewiez, S., Navari, R.M., Pendergrass, K.B., Lester, E.P., Bryson, J.C., and House, K.W.: A Double-Blind, Stratified Randomized Comparison of Intravenous (IV) Ondansetron Administered as a Multiple Dose Regimen Versus Two Single Dose Regimens in the Prevention of Cisplatin - Induced Nausea and Vomiting. ASCO 11: 1311, 1992.

31. Mailliard, J.A., Speyer, J.L., Hanson, K., Shaikh, B.S., Chang, A., Ryan, K., Navari, R.M., Berris, R.F., Schultz, J.J., Craig, J.B., Garcia, J., Ritch, B., Laufman, L.R., Shildt, R., Danier, P., Kaufman, A., Weitberg, A., Flynn, P.J., Stein, W., Pilch, Y.H., Guarino, M.J., Reynolds, R.D., Squillace, K., Kline, A., Scott, D., Banks, P.L.S., Jones, D., Bianchine, J. and Gams, R.A.: Prevention of Chronic Adriamycin Cardiotoxicity with the Bisdioxopiperazine Dexrazoxane (ICRF-187, ADR-529, Zinecard) in Patients with Advanced or Metastatic Breast Cancer. ASCO 11, 191, 1992.

32. Gucalp, R., Theriault, R., Gill, I., Madajewicz, S., Chapman, R., Navari, R.M., Ahmann, F., Knight, R. and Zelenakas, K.: Montefiori Medical Center, Bronx, N.Y., CIBA-GEIGY Corp., Summit, N.J. A Double-Blind Controlled Study of Two Infusion Regimens of 60mg Pamidronate Versus Saline in the Treatment of Hypercalcemia of Malignancy. ASCO 12: 1484, 1993.

33. Navari, R.M., Plezia, P., Kaplan, H.G., Gralla, R.J., Grunberg, S.M.: Single-Dose, Double-Blind, Multicenter Study Evaluating the Efficacy and Safety of Intravenous (IV) Granisetron in the Prevention of Cisplatin-Induced Nausea and Vomiting. ASCO 12: 1511, 1993.

34. Navari, R.M. and Palmer, R.: The Efficacy and Tolerance of Granisetron in the Prevention of High Dose Cisplatin-Induced Emesis. Supportive Care in Cancer, New Orleans, March, 1994.

35. Navari, R.M., Hesketh, P., Grote, T., Cramer, M., Law, R., Whitmore, J., Hahne, W.: A Double-Blind, Randomized, Comparative IV Study of Single-Dose Dolasetron Verses Ondansetron in Preventing Cisplatin - Related Emesis. ASCO 14: 1716, 1995

36. Ritter, H., Hall S., Mailliard, J., Navari, R.M., and Friedman, C.,: A Comparative clinical Trial of Granisetron and Ondansetron in the Prophylaxis of Cisplatin-Induced Emesis. ASCO 14: 1739, 1995.

37. Navari, R., Madajewicz, S., Anderson, N., Tchekmedyian, N., Whaley, W., Garewal, H., Beck, T., Anderson, E., Liddle, R., Ossi, M.: Oral Ondansetron Effectively Controls Cisplatin Induced Delayed Emesis. ASCO 14: 1720, 1995.

38. Beck, T., York, M., Chang, A., Navari, R., Harvey, W., Meshad, M., Kalman, L., Dobbs, T: Oral Ondansetron 8mg BID is as Effective as 8mg TID in the Prevention of Nausea and Vomiting Associated with Cyclophosphamide Based Chemotherapy. ASCO 14: 1781, 1995

39 Navari, R.M., Pendergrass, K.B., Grote, T.H., Kris, M.G., Ferguson, B.B., Nelson, A.M., Thomas, V., Allman, D.S., Pizzo, B., Baker, T.W., Chernoff, S.B.: All Oral Regimens of Dolesetron and Dexamethasone to Prevent Emesis Caused by High-Dose Cisplatin. ASCO 15: 1740, 1996.

40. Navari, R.M., Pendergrass, K.B., Grote, T.H., et al: Oral Dolasetron Plus Dexamethasone Delays Time to Emesis More Effectively Than IV Ondansetron or IV Dolasetron Alone in High-Dose Cisplatin Treated Patients. Ann. Oncol. 7: 657P, 1996.

41. Wada, J., Miranda, E., Justice, G. Eisenberg, P., Navari, R.M., et al: Oral Granisetron Given

as a Single 2mg Dose is Effective in the Prevention of Nausea and Vomiting Associated with High-Dose Cisplatin. Ann. Oncol. 7: 671P, 1996.

42. Hamm, J., Dimitrov, N., Vogel, C., Chang, A., Wasserheit, C., Navari, R.M., et al: A Phase III Study Utilizing Recombinant Human IL-6 With G-CSF Versus Placebo with G-CSF Following High Dose Cytoxan and Adriamycin in Patients with Advanced Breast Cancer. ASCO 16: 376, 1997.

43. Harris L., Winer E., Batist G., Rovira D., Navari R., et al. Phase III Study of TLC D-99 (Lipsome Encapsulated Doxorubicin) VS. Free Doxorubicin (DOX) in Patients with Metastatic Breast Carcinoma (MBC). ASCO 17:474, 1998.

44. Batist G., Winer E., Navari R., et al. Decreased Cardiac Toxicity by TLC D-99 (Liposome Encapsulated Doxorubicin in a Randomized Trial of Metastatic Breast Carcinoma (MBC). ASCO 17:443, 1998.

45. Navari R., Gralla R.J., Hesketh P., et al. L-754,030, A Selective Neurokinin-1 Antagonist Reduces Cisplatin-Induced Acute and Delayed Emesis: A Double Blind, Randomized Trial. ASCO 17:197, 1998.

46. Van Belle S, Reinhardt RR, Lichinitser M, Navari RM et al. Prevention of cisplatin-induced emesis by the selective neurokinin-1 antagonist, L-754,030, and its prodrug, L-758,298. ASCO 18:590a, 1999.

47. Navari RM, Stocking CA, Siegler M. Patient Decisions Concerning Palliative Care. ASCO 19:2437, 2000.

48. Alexander LN, Navari RM, Trick W, Kupronis B, Weinstein R, Solomon S. Dying To Get Off Antimicrobials. IDSA 430a, 2000.

49. Navari RM, Daskal F. Antimicrobial Use in Patients with Advanced Cancer Receiving End of Life Palliative Care. ASCO 20:1554, 2001.

50. Passik SD, Loehrer PJ, Navari RM, Nagy C, Sawi J, Jung S. A Phase I Trial of Olanzapine (Zyprexa) for the Prevention of Delayed Emesis in Cancer Patients Receiving Chemotherapy: A Hoosier Oncology Group Study. ASCO 21: 1492a, 2002.

51. Navari RM, Baxter LC, Jones KE. An Educational Intervention for Patients with a New Cancer Diagnosis. ASCO 21: 1415a, 2002.

52. Navari RM, Passik SD, Kirsh KK. Olanzapine and NK-1 Receptor Antagonists for the Prevention of Chemotherapy Induced Delayed Emesis. Psycho-Oncology 12: S146, 2003.

52. Navari RM, White PH. Effect of Antimicrobial Use on Symptoms of Patients with Advanced Cancer Receiving Hospice Care. ASCO 22:759 (Abstract 3053), 2003.

53. Navari RM. New Agents for the treatment of Chemotherapy Induced Nausea and Vomiting. American Psychosocial Oncology Society, First Annual Conference 1:21, 2004.

53. Navari RM, Einhorn LH, Loehrer PJ, et al. A phase II trial of olanzapine for the prevention of chemotherapy induced nausea and vomiting (CINV). ASCO 23:736 (Abstract 8046), 2004.

54. Wilson MN, Navari RM Role of Depression in the Treatment Choices of Patients with Early Stage Breast Cancer. Psycho-Oncology 14: S44, 2005.

55. Navari RM, Reinbolt RE, Shenk AM, White PH. Symptomatic Treatment of Infections in Patients with Advanced Cancer Receiving Hospice Care. ASCO 24:746s (Abstract 8069), 2005.

56. Navari RM, Einhorn LH, Loehrer, PJ, et al. A phase II trial of olanzapine and palonosetron for the prevention of chemotherapy induced nausea and vomiting (CINV). J Clin Oncol 24 (18s): 495s (Abstract 8608), 2006.

57. Navari RM, Buckingham L End of life decisions by adults with cancer: Role of religious practices and spiritual beliefs. J Clin Oncol 25 (18s): 509s (Abstract 9067), 2007.

58. Jackson SA, Hamlett W, Navari RM. A transformational integrative team-based-learning (TBL) curricular reform for the first two years of medical education: The Indiana University School of Medicine South Bend model. AAMC-CGEA. #68, Indianapolis, March, 2007.

59. Jackson SA, Hamlett W, Navari RM. Using self and peer assessment in the team-based-learning process. Team Based Learning Annual Conference Proc., pp 7,8, 2007.

60. Navari RM, Huotilainen K, Lisle GA. Indiana University and Notre Dame: Sharing a facility, sharing success. Society for College and University Planning, July, 2007, Chicago.

61. Navari RM. Pathogenesis of antiemetic therapies. J Support Oncol 5:399, 2007.

62. Jackson SA, McKee E, Navari RM. A transformational integrative team-based-

learning (TBL) curricular reform for the first two years of medical education: The Indiana University School of Medicine South Bend model. AAMC-CGEA. #91, Columbus, April, 2008.

63. Navari RM, Brenner MC Treatment of cancer-related anorexia with olanzapine and megestrol acetate. J Clin Oncol 26 (15S): 520s (Abstract 9576), 2008.

64. Navari RM, Brenner MC Olanzapine and megestrol acetate for cancer related anorexia. Psycho-Oncology 18:S47, P1-22, 2009.

65. Jackson SA, McKee EE, Navari RM Peer and self assessment: An innovative approach to training and implementation in a TBL environment. Team Based Learning Annual Conference, pp 3, 2009.

66. Navari RM, Gray SE Treatment of chemotherapy-induced breakthrough nausea and vomiting. J Clin Oncol 27, suppl, Abstract e20536, 2009.

67. Navari RM, Brenner MC Treatment of cancer related anorexia with olanzapine and megestrol acetate. Supportive Care Cancer 17: 971, 2009.

68. Navari RM, Gray SE Treatment of chemotherapy-induced breakthrough nausea and vomiting. Psycho-Oncology 19, P2-32, 2010.

69. Navari RM, Gray SE, Carr AC Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV): A randomized phase III trial. J Clin Oncol 28, 15S, 641s (Abstract 9020), 2010.

70. Navari RM, Gray SE, Carr AC Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Support Care Cancer 18, supp 3, S81 (Abstract 02-010), 2010.

71. Navari RM, Gray SE, Carr AC Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A Randomized Phase III Trial. Psycho-Oncology 21, P2-51, 2012.

72. Navari RM Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy**.** Support Care Cancer 20, S47, Abstract 167, 2012.

73. Navari RM, Nagy CK, Gray SE. Olanzapine versus metoclopramide for the treatment of

breakthrough chemotherapy induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. J Clin Oncol 30, 2012 (supp; abstr 9064).

74. Navari RM Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Blood 120, Abstract 191, 2012.

75. Navari RM Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy**.** Psycho-Oncology 22, 14-1, 2013.

76. Navari RM, Brenner MC, Wilson MN Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. J. Clin Oncol 31, 2013 (supp; abstr 9631).

77. Navari RM Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Support Care Cancer 21, S126, Abstract 360, 2013.

78. Rapoport BL, Poma A, Hedley ML, Martell RE, Navari RM Phase 3 trial results for Rolapitant**,** a novel NK-1 receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in subjects receiving highly emetogenic chemotherapy. J Clin Oncol 32, 2014 (sup: abstr 9638).

79. Rapoport BL, Poma A, Hedley ML, Martell RE, Navari RM Phase 3 trial results for Rolapitant**,** a novel NK-1 receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in subjects receiving highly emetogenic chemotherapy. Support Care Cancer 22, S100, Abstract 387, 2014.

80. Snow RC, Nagy C, Arora S, Poma A, Navari RM Rolapitant, a novel NK-1 receptor antagonist, phase 3 trial results in the prevention of chemotherapy-induced nausea and vomiting in subjects receiving highly or moderately emetogenic chemotherapy. Oncology Nursing Society Annual Meeting, 2015.

81. Navari RM, Nagy CK Olanzapine versus fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving concurrent chemo-radiation therapy: a randomized, double-blind, phase III trial. J Clin Oncol 33, 2015 (suppl; abstract 9502).

82. Chasen M, Urban L, Schnadig I, Rappaport BL, Poma A, Arora S, Navari RM, Schwartzberg LS, Gridelli C Impact of rolapitant on quality of life in patients receiving highly and moderately emetogenic chemotherapy. . J Clin Oncol 33, 2015 (suppl; abstract 9615).

83. Nagy C, Clark-Snow R, Arora S, Powers D, Navari RM. Rolapitant for the Prevention of Nausea in Patients Receiving Moderately or Highly Emetogenic Chemotherapy. Oncology Nursing Society Annual Meeting, 2016.

84. Navari RM, Qin R Ruddy KJ et al. Olanzapine For The Prevention Of Chemotherapy- Induced Nausea And Vomiting (CINV) In Patients Receiving Highly Emetogenic Chemotherapy (HEC): Alliance A221301, A Randomized, Double-Blind, Placebo-Controlled Trial. J Clin Oncol 33 (suppl 29S):abstract 176, 2015.

85. Rapoport B, Schwartzberg L, Arora S, Powers D, Jordan K, Navari RM. Rolapitant for control of chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer. . J Clin Oncol 34, 2016 (suppl; abstract 10122).

86. Schwartzberg L, Navari RM, Arora S et al. Rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer. J Clin Oncol 34, 2016 (suppl; abstract 10121).

87. Navari RM, Rapoport B, Arora S et al. Rolapitant for the control of chemotherapy-induced nausea and vomiting in patients with lung cancer. Support Care Cancer 24, S51, Abstract PS084, 2016.

88. Schwartzberg L, Navari RM, Arora S et al. Rolapitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer. Support Care Cancer 24, S51, Abstract PS086, 2016.

89. Rapoport B, Schwartzberg L, Arora S, Powers D, Jordan K, Navari RM. Rolapitnat for the cont5rol of chemotherapy-induced nausea and vomiting in patients with gynecological cancer. Support Care Cancer 24, S85, Abstract eP018, 2016.

90. Navari RM, Nagy C, Arora S et al Rolapitant for the prevention of nausea in patients receiving moderately or highly emetogenic chemotherapy. Support Care Cancer 24, S84, Abstract eP016, 2016.

91. Chiu L, Chow R, Popovic M, Navari RM et al. Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systemic review and meta analysis. Supportive Care Cancer 24, S80, Abstract eP018, 2016.

92. Navari RM, Nagy C, Arora S et al. Rolapitant for the prevention of nausea in patients receiving moderately or highly emetogenic chemotherapy. J Clin Oncol 34 (suppl

30S): abstract 224, 2016.

93. Rapoport B, Schwartzberg L, Arora S, Powers D, Jordan K, Navari RM. Rolapitnat for the cont5rol of chemotherapy-induced nausea and vomiting in patients with gynecological cancer. J Clin Oncol 34 (suppl 30S): abstract 223, 2016.

94. Navari RM, Jordan, Rapoport B et al. Rolapitnat for the control of chemotherapy-induced nausea and vomiting in patients with gastrointestinal and colorectal cancers J Clin Oncol 34 (suppl 30S) :abstract 222, 2016.

95. Navari RM, Jordan K, Rapoport B et al. Efficacy of rolapitant for the prevention of chemotherapoy-induced nausea and vomiting in patients with gastrointestinal and colorectal cancers. Ann Oncol, in press, abstract 1440P, 2016.

96. Schwartzberg L, Jordan K, Rapoport B, Schnadig I, Chasen M, Arora S, Barbour S, Powers D, Navari RM Safety of rolapitant for prevention of chemotherapy-induced nausea
and vomiting in patients receiving breast cancer resistant protein substrate chemotherapy agents. Ann Oncol, in press, abstract 1442P, 2016.

97. Chow R, Chiu L, Navari RM et al. Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies:

A systematic review. Supportive Care Cancer 25, Abstract eP007, 2017.

98. Chiu L, Chow R, Popovic M, Navari RM et al. efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV); A systematic review and meta-analysis. Supportive Care Cancer 25, Abstract eP005, 2017.

99. Navari RM, Nagy C, Rapoport BL, et al. Rolapitant for the prevention of nausea in patients receiving cisplatin and carboplatin-based chemotherapy: Alternative methods for evaluating nausea. Supportive Care Cancer 25, Abstract eP017, 2017.

100. Navari RM. Nausea associated with advanced cancer. J Clin Oncol 35 (suppl):abstract 3, 2017.

101. Roeland EJ, Ruddy KJ, Leblanc TW, Binder G, Lafleur F, Amari DT, Surinach A, Wu Z, Navari RM. Gaps in compliance with current antiemetic guidelines for highly emetogenic chemotherapy. NCCN Annual Conference, March, 2018.

102. Roeland EJ, Ruddy KJ, Leblanc TW, Binder G, Amari DT, Surinach A, Navari RM. Antiemetic guideline compliance of neurokinin-1 receptor antagonists in the

highly emetogenic chemotherapy setting. Supportive Care Cancer 26 (Suppl 2) 539-5364, abstract eP017, 2018.

103. Kim H, Morgan DE, Schexnailder P, Navari RM et al. Accurate therapeutic response Assessment of pancreatic ductal adenocarcinoma using quantitative DCE-MRI with novel perfusion phantom: A pilot study. RSNA 2018 Annual Meeting, November, 2018.

104. Navari RM, Ruddy KJ, LeBlanc TW et al. Impact of addition of carboplatin AUC ≥ 4 to guidelines for triplet antiemetic prophylaxis: a gap in quality care and guideline adoption. Advanced Practitioners Society for Hematology & Oncology Annual Conference, November, 2018.

105. Roeland EJ, Ruddy KJ, LeBlanc TW, Nipp R, Binder G, Sebastiani S, Potluri R, Schmerold LM, Papademetriou E, Navari RM. What the HEC? Physician variation and attainable compliance targets in antiemetic prophylaxis. ASCO Palliative and Supportive Care Symposium; November, 2018.

106. Williams GR, Kenzik KM, Parham M, Rocque GB, McDonald A, Paluri R, Navari RM et al. Integrating geriatric assessment into routine gastrointestinal consultation: The Cancer and Aging Resilience Evaluation. ASCO GI Symposium, November, 2018.

107. Varnado W, Kenzik KM, McDonald A, Parman M, Paluri R, Navari RM et al. Financial Distress amongst older adults with gastro-intestinal malignancies. ASCO GI Symposium, November, 2018.

108. Navari RM, Ruddy KJ, LeBlanc TW et al. Physician concordance with update to ASCO guidelines for antiemetic use with carboplatin AUC ≥ 4. J Clin Oncol 37 (suppl):abstract 3 2019.

109. Navari RM, Ruddy KJ, LeBlanc TW et al. Physician concordance with update to ASCO guidelines for antiemetic use with carboplatin AUC ≥ 4. Supportive Care Cancer 27 (Suppl 2) abstract, 2019.

110. Roeland EJ Ruddy KJ, , LeBlanc TW, Wickham RJ, Clark-Snow R, Binder G, Sebastiani S, Potluri R, Schmerold LM, Navari RM Ondansetron versus palonosetron as a marker of non-adherence to antiemetic prophylaxis guidelines in highly emetogenic chemotherapy. Supportive Care Cancer 27 (Suppl 2) abstract, 2019.

111. Navari RM, Pywell CM, Le-Rademacher JG, White PH, Dodge AB, Albany C, Loprinzi CL A placebo controlled, randomized, double-blinded trial of olanzapine for the treatment of chronic nausea and/or vomiting, unrelated to chemotherapy/radiation. ASCO Palliative and Supportive Care Symposium; Abatract 118, October, 2019.

112. Schwartzberg l, Ruddy KJ, Navari RM et al. Avoidable acute care involving chemotherapy-induced nausea and vomiting among patients with breast cancer receiving anthracycline + cyclophosphamide with NEPA prophylaxis relative to other antiemetics: An external control
arm analysis. San Antonio Breast Cancer Symposium, December, 2019.

113. Navari RM, Bonizzoni E, Wickham R, Clark-Snow R Pooled analysis of phase 3 studies comparing a single-dose of fixed combination of netupitant/palonosetron (NEPA) versus a 3-day aprepitant-based regimen (APR) for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC), BP12--019 NCCN Conference, March, 2020.

114. Roeland EJ, Navari RM, Ruddy KJ et al. Acute care and hydration due to CINV among patients receiving NEPA prophylaxis for AC chemotherapy. ASCO Palliative and Supportive Care Symposium; Abatract 112, October, 2019.

115. Navari RM, Binder G, Roeland EJ et al. Duration of chemoterapy-induced nausea and Vomiting (CINV) as a predictor of later-cycle CINV. San Antonio Breast Cancer Symposium, Abstract PS 13-27, 2020.

116. Navari RM, Binder G, Molassiotis A et al. Chemotherapy-induced nausea and vomiting (CINV) risk after prior breakthrough CINV: Unmasking the false average. San Antonio Breast Cancer Symposium, Abstract PS 13-07, 2020.

117. Navari RM, Mosier MC Incidence of intravenous hydration post anthracycline-cyclophosphamide chemotherapy in breast cancer. San Antonio Breast Cancer Symposium, Abstract PS 57-61, 2020.

118. Binder G, Scott JA, Schwartzberg, L, Roeland EJ, Gingras l, Navari RM. Avoiding acute care and unplanned hydrations from chemotherapy-induced nausea and vomiting in real world practice. Academy of Managed Care Pharmacy Annual Meeting, April, 2021.

119. Navari RM, Binder G, Bonizzoni E, Clark-Snow R, Olivari Tilola S, Roeland E Assessing duration of breakthrough chemotherapy-induced nausea and vomiting (CINV): A pooled study analysis of NEPA versus aprepitant. ASCO 2021 (Abstract 12091).

120. Chow R, Herrstedt J, Aapro M, Chiu L, Lam, H, Prsic E, Lock M, DeAngelis C, Navari RM Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature. MASCC 2021 (Abstract).

121. Navari RM, Binder G, Bonizzoni E, Clark-Snow R, Olivari Tilola S, Roeland E Evaluating duration of breakthrough chemotherapy-induced nausea and vomiting (CINV): A pooled study analysis of NEPA versus aprepitant. MASCC 2021 (Abstract).

122. Navari RM, Chrápavá M, Karlínová B, Kellnerová R, Binder G, Aapro M Duration of breakthrough chemotherapy-induced nausea and vomiting (CINV) as a risk factor for repeated CINV: Analysis of the Nausea/Emesis Registry in Oncology (NERO). MASCC 2021 (Abstract).

123. Navari RM, Le-Rademacher J, Smieliauskas F et al. Olanzapine with or without an NK-1 receptor for preventing chemotherapy induced nausea and vomiting in patients receiving highly emnetogenic chemotherapy: A phase III randomized, double-blind placebo-controlled trial. ASCO 2022 (abstracvt).

124. Navari RM, Nelson W, Utt JK et al. Real world treatment outcomes and health care resource use associated with antiemetics among cancer patients on highly emetogenic platinum-based chemotherapy.ASCO 2022 (abstract).

PATENTS:

1. Navari, RM, Prorok M, Castellino, FJ Cathepsin E as a marker of colon cancer. U.S. Patent 7,892,750, 2/22/2011.
2. Navari, RM Cathepsin E as a marker of colon cancer. U.S. Patent 8,637,265, 1/28/2014.

CURRENT PROJECTS / FUNDING:

1. **Navari RM,** Principal Investigator: Alliance 221301: A multi-institutional Phase III trial: Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. National Cancer Institute, Community Clinical Oncology Trials, $2,100,000; November, 2018 – June, 2021.

2. **Navari RM,** Co-investigator: Indiana Clinical and Translational Sciences Initiative: Engineering micellular nanoparticles in overcoming drug resistance in multiple myeloma. $75,000: 2018-2021.

3. **Navari RM,** Principal Investigator: J. W. Anderson Foundation: A Phase II trial for the detection of tumor marker Cathepsin E in patients with colon cancer. $200,000: 2018-2022.

4. **Navari RM,** Co-investigator: Indiana Clinical and Translational Sciences Initiative: Advancement of new anti-cancer agents. $75,000, 2018-2022.

5. **Navari RM,** Principal Investigator: Alliance Clinical Oncology Trials Group: A multi-institutional Phase III trial: Olanzapine for the treatment of chronic nausea in patients with cancer. National Cancer Institute, $153, 852, 2016-2021.

6. **Navari RM,** Principal Investigator: Alliance Clinical Oncology Trials Group: A multi-institutional Phase III trial: Olanzapine with or without an NK-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. National Cancer Institute, $3,900,000, September, 2018-September, 2021.

7. **Navari RM,** Principal Investigator, Olanzapine plus NEPA for the prevention of chemotherapy-induced nausea and vomiting in patients receiving multi-day, highly emetogenic chemotherapy prior to SCT: a randomized, phase III, multi-institutional, clinical trial. Helsinn, USA, $1,650,000, September, 2018 – June, 2021

8. **Navari RM**, co-investigator, Second generation anti-PD-1 inhibitor for the treatment of advanced stage non-small cell lung cancer. Phase I-II clinical trial. Bristol-Myers, Inc.

9. **Navari RM,** Principal Investigator, Prospective, Observational Study of the Safety, and Tolerability of CINVANTI^{TM} Administered as an Intravenous Infusion or Injection in Patients Receiving Highly Emetogenic or Moderately Emetogenic Chemotherapy. Heron Therapeutics, Inc. $185,000, October, 2018 - December, 2022.

10. **Navari RM**, Principal Investigator, Granisetron Extended Release Sucutaneous Injection for patients receiving moderately or highly emetiogenic chemotherapy who develop breakthrough CINV after receiving palonosetron in their first cycle of chemotherapy. Heron Therapeutics, Inc. $255,000, November, 2019 – December, 2022.

11. **Navari RM,** Principal Investigator, NEPA with or without olanzapine for patients receiving moderately or highly emetiogenic chemotherapy who develop breakthrough CINV after their first cycle of chemotherapy. Helsinn USA, $375,000, January, 2020 – January 2022.

12. Jatoi A, Smith T, **Navari RM**, Loprinzi CL A Randomized, Double-Blinded Trial of Olanzapine Versus Placebo for Cancer-Associated Anorexia.
Alliance Clinical Oncology Trials Group. National Cancer Institute, $3,500,000, March, 2021- June, 2023.

13. Navari RM, Loprinzi CL, A Randomized, Double-Blinded Trial of Olanzapine Versus Placebo for Abdominal Radiotherapy-Induced nausea/Vomiting.
Alliance Clinical Oncology Trials Group. National Cancer Institute, July, 2021- August, 2022.